The GLP-1 Effect: How Weight-Loss Drugs Are Reshaping CVS

Prologue: The Reckoning

In the summer of 2026, CVS Health’s second quarter earnings report delivered a dramatic reversal from a year ago. Net income tripled to $3.0 billion. Aetna’s medical benefit ratio reported 87.4% for Q2 2026, comparing favorably to 89.9% recorded in Q2 2025. And, stock was up 32% year-over-year. However, these headline numbers obscured a much bigger transformation underway at CVS.

Metric	Q2 2025	Q2 2026	Change
Total Revenue	$98.9B	$106.1B	+7.3%
Net Income	$1.01B	$3.00B	+195.7%
Operating Income	$2.38B	$4.70B	+97.5%
Adjusted Operating Income	$3.81B	$5.16B	+35.4%
GAAP EPS	$0.80	$2.31	+188.8%
Adjusted EPS	$1.81	$2.58	+42.5%
Aetna Medical Benefits Ratio	89.9%	87.4%	-250bps

Matthews™ has been tracking CVS’s shift in the marketplace for more than a year. In late 2025, we looked at how CVS was pruning underperforming stores and business lines while directing resources toward healthcare-oriented formats and stronger locations.

By late 2026, that transition was increasingly visible in the real estate itself. Gone were the days when investors could value nearly every drugstore property on the strength of the CVS or Walgreens corporate name. Now, value is increasingly placed on individual store performance, lease structure, and location.

More recently, we explored another pressure point. The growing regulatory challenge to vertically integrate the PBM-pharmacy model that has long been central to CVS’s strategy.

Now, another force is accelerating that transformation: GLP-1s

The rapid utilization of weight-loss drugs comes at a pivotal moment for CVS as three major pressures converge:

1. The Federal Trade Commission had just forced Caremark (CVS’s Pharmacy Benefit Manager and historic profit engine) to abandon the pricing practices that had made it so lucrative.
2. Amazon is expanding same-day prescription delivery to 4,500 cities, including drone delivery to 500 communities.
3. Changing consumer behavior is challenging the traditional drugstore model and forcing CVS to rethink how patients access prescriptions and care.

But GLP-1s are different. They touch almost every part of the CVS ecosystem. CVS had a choice. It could defend its traditional vertically integrated fortress, PBM, insurance, pharmacy, against these assaults. Or it could transform into something entirely different.

From Aetna paying for them to Caremark negotiating access to them, CVS pharmacies dispensing them, and the Company’s healthcare businesses managing the patients that take them. GLP-1s may be the first major test of whether CVS can turn its integrated healthcare model into a competitive advantage as economics of insurance, pharmacy benefits, and prescription access continue to change.

Goldman Sachs Research projects that the market could reach $100 billion annually by 2030, making GLP-1s one of the most sought-after opportunities across the healthcare industry.

Part 01: How CVS Built the Perfect Healthcare Fortress

To understand why GLP-1s matter so much to CVS, it helps to understand the system and company spent decades building.

• Caremark: The second-largest PBM in America, controlling which drugs were covered, how much pharmacies were paid, and where patients filled prescriptions
• Aetna: One of the nation’s largest health insurers, with 26 million members
• Retail pharmacies: 9,000 retail pharmacy locations
• MinuteClinic: Thousands of walk-in clinics embedded in stores
• Oak Street Health: Primary care clinics for Medicare patients
• Signify Health: Home health services

But the model that fueled CVS’s growth, increasingly became a problem and a source of vulnerability. Its scale and vertical integration attracted regulators, competitors, and growing public criticism of how prescription drugs are priced and distributed.

Part 02: The Cracks in the Armor

The FTC Settlement: A Profit Engine Is Dismantled

On July 14, 2026, the Federal Trade Commission announced a settlement with Caremark that changed how the PBM would operate.

Here are the regulations:

• Spread pricing eliminated: The difference between what plan sponsors paid Caremark and what Caremark paid pharmacies, a key profit source, was abolished
• Point-of-sale rebates required: Rebate benefits had to flow directly to consumers at the pharmacy counter, not into Caremark’s pockets
• Reimbursement reformed: Pharmacies had to be compensated based on actual drug acquisition costs plus a dispensing fee
• No discrimination against low-cost drugs: Caremark could no longer favor high-priced versions of medications

The FTC estimated the settlement would generate $8.5 billion in consumer savings over 10 years. For consumers, this was a victory. For CVS, the settlement represented a change to the economics of a business model that had historically been central to its integrated system.

CFO Brian Newman acknowledged the challenge. Weaker conditions in the 340B federal drug discount program would also create headwinds. Caremark membership would decline in 2027 as clients exited and retention tracked below historical levels.

Management’s message was unmistakable: The profit engine that had powered CVS’s integrated model was sputtering.

The State-Level Assault on PBMs

The pressure on CVS is not limited to federal regulations. States including Arkansas, California, Florida, and Tennessee have pursued legislation limiting PBM practices, from spread pricing, patient steering, and ownership of pharmacies by PBMs.

The most consequential proposal is in Tennessee where state lawmakers passed the FAIR Rx Act (SB 2040) in May 2026. This bill makes Tennessee the second state to ban PBMs from owning pharmacies. The message to CVS could not be more clear the regulatory assault on its integrated model is not a series of isolated incidents but a coordinated national campaign

For CVS, this creates a structural challenge. The integration of Caremark, Aetna, and CVS Pharmacy was designed to create an advantage by connecting multiple parts of the healthcare system. However, regulators are increasingly questioning whether that same integration creates conflicts of interest. What once differentiated CVS is now one of the central pressures forcing the company to evolve.

“No company should be able to write the rules, steer the patient, set the payment, and then own the pharmacy that profits from the transaction,”

– Bobby Harshbarger, Tennessee State Senator

Part 03: The Transformation Begins

In June 2026, CVS expanded its GLP-1 strategy, using its network of 9,000+ pharmacies and MinuteClinic services to build a more integrated weight-management platform. The strategy gives CVS an opportunity to engage patients across multiple points of care, including:

• Virtual consultations through MinuteClinic starting at $29
• Discounted medication access, with GLP-1s starting at $25 per month
• Same-day pickup at 9,000 pharmacies
• One-on-one patient support for adherence and side-effect management
• Participation in the CMS Medicare GLP-1 Bridge Program starting July 1, 2026

Ultimately bringing together CVS’s traditional strengths with the healthcare model it is trying to build. Its pharmacy network, MinuteClinic services, digital capabilities, and patient support infrastructure give CVS multiple opportunities to participate in the patient journey, even when it does not begin with Aetna or Caremark.

Launching Health100: Building the Replacement for the Old Model

In March 2026, CVS announced a $20 billion, decade-long partnership with Google Cloud to build Health100, an AI-powered platform designed to become the operating system for consumer healthcare.

Health100 would aggregate data from benefit managers, pharmacies, providers, and digital health tools into a single consumer-facing experience. It would provide price transparency, personalized health management, and seamless access across the entire healthcare system.

It wasn’t just for CVS customers or CVS services. It was an ecosystem where other health innovators could build applications.

The initial rollout began in 2026 with Haio, an AI-powered assistant. Early results were encouraging, but management was careful not to include any Health100 revenue in 2026 guidance.

Automating the Supply Chain

While Health100 attacked the digital front end, CVS was already transforming its physical operations.

The first highly automated warehouse opened in Hainesport, New Jersey, with a second automated facility in Lumberton. Together, these facilities represented a fundamental rethinking of how CVS got products to stores.

Supply Chain: The Foundation of Transformation

The supply chain automation wasn’t just about cost savings. It was about creating a foundation for the new CVS.

The automated warehouses enabled:

• Precision replenishment: Getting exactly the right items to each store, eliminating waste and ensuring availability
• Small-store support: Making the pharmacy-only format viable by providing precise, just-in-time delivery
• Cost structure improvement: Reducing operating costs by 40% per facility, creating margin to invest in growth
• Scale: Processing millions of items weekly with a fraction of the staff, enabling expansion without proportionate cost increases

But the goal wasn’t just efficiency. It was accuracy. As Josh White, CVS’s chief supply-chain and logistics officer, explained:

“The entire point of doing this was to drive incredibly high levels of accuracy and therefore product availability on shelves.”

Without these changes, CVS could not abandon its large footprint locations and compete with delivery competitors.

Rightsizing the Retail Footprint

After closing nearly 1,000 locations over the past three years, CVS is changing course and opening new stores. However, these are not the sprawling, general-merchandise drugstores of the past.

In 2026, CVS plans to open approximately 60 new locations, including a 3,000 square foot “apothecary-style” pharmacy-only store, an initiative born from declining front-end retail sales and a strategic shift toward being a healthcare-led company.

It is a direct response to consumer data from CVS’s own 2025 Rx Report, which found that 80% of patients prefer in-person pharmacy care and 97% of pharmacy professionals believe in-person interactions remain vital.

Notably, these pharmacy-only locations do not include attached MinuteClinics, a significant departure from CVS’s previously stated goal of integrating primary care within its stores. This suggests that, for the physical retail footprint, CVS is embracing a more pragmatic “back-to-basics” strategy, refocusing on its core competencies as a pharmacist-led, relationship-based business before layering on more complex clinical services. The model is rolling out alongside more than 40 traditional stores and locations within Target, creating a multi-format strategy that lets CVS serve communities with different needs.

The Amazon Counter-Strike

Amazon represents a fundamentally different competitive threat. Rather than replicating CVS’s vertically integrated model, Amazon has focused on making individual parts of the healthcare experience faster, more convenient, and increasingly digital.

By mid-2026, Amazon had built a formidable healthcare ecosystem:

• Amazon Pharmacy: Same-day delivery to 4,500 cities
• One Medical: Primary care clinics with AI tools that reduced physician administrative time by 40%
• Prime Air: Drone delivery to nearly 500 cities
• RxPass: Discounted prescriptions for Prime members
• Same-day GLP-1 delivery: Oral Ozempic to 3,000 cities, expanding to 4,500 by year-end

For CVS, the challenge is no longer simply getting patients into a pharmacy. It is giving them a reason to remain within the CVS ecosystem. Competing with Amazon requires more than matching delivery speed. CVS has to make its pharmacy access, clinical care, digital tools, insurance, and patient support more valuable than convenience alone.

Part 04: The Road Ahead

The 2027 Headwinds:

• FTC settlement impact: The transition to flat fee-based compensation for Caremark would create margin compression
• 340B pressure: Manufacturer restrictions on covered entities and large specialty drugs becoming generic would reduce earnings
• Caremark membership loss: Retention was tracking below historical levels, and customer market exits would reduce membership
• State-level regulation: New laws and proposals in states including Tennessee, Arkansas, California, and Florida placing increasing pressure on PBM practices and challenge ownership structures.

The challenge for CVS is one of timing.

CVS is attempting to replace one competitive advantage with another. The old CVS was built around vertical integration. The emerging CVS is focused on connecting capabilities in new ways. GLP-1s provide an early test of that strategy, while Health100 takes it a step further.

CVS’s transformation is far from complete, and whether the new model can replace the economics of the old one remains to be seen. But the direction is clear: GLP-1s may offer the real test of whether the new CVS can work.